Astria Therapeutics, Inc.
US ˙ NasdaqGM ˙ US04635X1028
DETTE SYMBOL ER IKKE LÆNGERE AKTIVT

SecurityATXS / Astria Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership100,427 shares
Latest Disclosed Value $ 1,314,590
Barclays Plc reports 6.24% decrease in ownership of ATXS / Astria Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 100,427 shares of Astria Therapeutics, Inc. (US:ATXS) valued at $1,314,589 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 107,109 shares of Astria Therapeutics, Inc.. This represents a change in shares of -6.24% during the quarter. The current value of the position is $1,263,372 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F ASTRIA THERAPEUTICS COM 04635X102 100,427 -6,682 -6.24 1,315 68.68 0.0003
2026-03-31 2025-09-30 13F/A-3 ASTRIA THERAPEUTICS COM 04635X102 107,109 -10,425 -8.87 780 23.85 0.0002
2026-03-19 2025-09-30 13F/A-2 ASTRIA THERAPEUTICS COM 04635X102 92,651 -24,883 1,020 0.0003
2025-11-12 2025-09-30 13F ASTRIA THERAPEUTICS COM 04635X102 107,109 -10,425 780 0.0002
2026-02-27 2025-06-30 13F/A-2 ASTRIA THERAPEUTICS COM 04635X102 117,534 44,901 61.82 630 62.53 0.0001
2025-08-14 2025-06-30 13F/A-1 ASTRIA THERAPEUTICS COM 04635X102 117,534 44,901 1 0.0001
2025-08-13 2025-06-30 13F ASTRIA THERAPEUTICS COM 04635X102 117,534 44,901 1 0.0000
2026-03-17 2025-03-31 13F/A-1 ASTRIA THERAPEUTICS COM 04635X102 72,633 -25,187 -25.75 388 -55.72 0.0001
2025-05-15 2025-03-31 13F ASTRIA THERAPEUTICS COM 04635X102 72,633 -25,187 0 0.0001
2026-03-19 2024-12-31 13F/A-1 ASTRIA THERAPEUTICS COM 04635X102 97,820 5,169 5.58 875 -14.31 0.0002
2025-02-13 2024-12-31 13F ASTRIA THERAPEUTICS COM 04635X102 97,820 5,169 1 0.0002
2026-03-31 2024-09-30 13F/A-2 ASTRIA THERAPEUTICS COM 04635X102 92,651 38,321 70.53 1,020 106.48 0.0003
2024-11-19 2024-09-30 13F/A-1 ASTRIA THERAPEUTICS COM 04635X102 92,651 38,321 1 0.0003
2024-11-15 2024-09-30 13F ASTRIA THERAPEUTICS COM 04635X102 92,651 38,321 1 0.0001
2026-03-23 2024-06-30 13F/A-1 ASTRIA THERAPEUTICS COM 04635X102 54,330 -80,877 -59.82 494 -74.04 0.0002
2024-08-14 2024-06-30 13F ASTRIA THERAPEUTICS COM 04635X102 54,330 -80,877 0 0.0002
2026-03-24 2024-03-31 13F/A-1 ASTRIA THERAPEUTICS COM 04635X102 135,207 85,793 173.62 1,903 402.11 0.0007
2024-05-15 2024-03-31 13F ASTRIA THERAPEUTICS COM 04635X102 135,207 85,793 2 0.0007
2026-03-25 2023-12-31 13F/A-1 ASTRIA THERAPEUTICS COM 04635X102 49,414 40,996 487.00 380 511.29 0.0001
2024-02-15 2023-12-31 13F ASTRIA THERAPEUTICS COM 04635X102 49,414 40,996 0 0.0001
2026-03-26 2023-09-30 13F/A-1 ASTRIA THERAPEUTICS COM 04635X102 8,418 -592 -6.57 63 -17.33 0.0000
2023-11-07 2023-09-30 13F ASTRIA THERAPEUTICS COM 04635X102 8,418 -592 0 0.0000
2026-03-30 2023-06-30 13F/A-2 ASTRIA THERAPEUTICS COM 04635X102 9,010 -23,987 -72.69 75 -82.88 0.0000
2023-09-20 2023-06-30 13F/A-1 ASTRIA THERAPEUTICS COM 04635X102 9,010 -23,987 0 0.0000
2023-08-03 2023-06-30 13F ASTRIA THERAPEUTICS COM 04635X102 9,010 -23,987 0 0.0000
2026-03-30 2023-03-31 13F/A-1 ASTRIA THERAPEUTICS COM 04635X102 32,997 32,997 439 0.0002
2023-05-04 2023-03-31 13F ASTRIA THERAPEUTICS COM 04635X102 32,997 32,997 0 0.0002
2021-11-09 2021-09-30 13F CATABASIS PHARMACEUTICALS IN COM 14875P206 0 -5,311 -100.00 0 -100.00
2021-08-13 2021-06-30 13F CATABASIS PHARMACEUTICALS IN COM 14875P206 5,311 -31,615 -85.62 11 -89.72 0.0000
2021-05-13 2021-03-31 13F CATABASIS PHARMACEUTICALS IN COM 14875P206 36,926 10,392 39.16 107 87.72 0.0001
2021-02-11 2020-12-31 13F CATABASIS PHARMACEUTICALS IN COM 14875P206 26,534 17,776 202.97 57 5.56 0.0000
2020-11-12 2020-09-30 13F CATABASIS PHARMACEUTICALS IN COM 14875P206 8,758 -1,155 -11.65 54 -15.62 0.0000
2020-08-12 2020-06-30 13F CATABASIS PHARMACEUTICALS IN COM 14875P206 9,913 9,913 64 0.0000
2018-08-14 2018-06-30 13F CATABASIS PHARMACEUTICALS IN COM 14875P107 0 -1,776 -100.00 0 -100.00
2018-05-15 2018-03-31 13F CATABASIS PHARMACEUTICALS IN COM 14875P107 1,776 1,776 3 0.0000
2016-11-14 2016-09-30 13F CATABASIS PHARMACEUTICALS IN COM 14875P107 0 -88 -100.00 0 0.0000
2016-08-12 2016-06-30 13F CATABASIS PHARMACEUTICALS IN COM 14875P107 88 88 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.